Researchers have identified a distinct gene expression program associated with neurotransmission in the living human brain. The study combines molecular data with real-time physiological recordings, revealing a coordinated set of genes whose activity tracks with neuronal signaling.
A new study by Mount Sinai researchers found that distributed multi-agent AI systems can maintain superior accuracy levels while using significantly fewer computing resources compared to single-agent designs. This approach can help healthcare organizations scale AI without sacrificing quality or safety.
The collaboration aims to understand why IBD runs in some Saudi families and develop personalized treatment options. By studying well-characterized families with multiple members affected, researchers hope to identify exposure and biological markers that drive disease mechanisms and outcomes.
The ORIGIN study uses advanced molecular tools to identify risk factors and early warning signals in stored blood samples from up to 13,000 service members. By analyzing these data, researchers aim to predict and prevent diseases such as cancer, heart disease, and autoimmune disorders years before symptoms appear.
Researchers found that young mice developed strong skin inflammation in response to everyday allergens, revealing a brief window of vulnerability. The study suggests that early childhood represents a critical period for immune-driven skin disease, and that targeting this period may prevent allergic diseases from spreading.
A recent study has found that ChatGPT Health may fail to direct users appropriately to emergency care in serious cases, and its suicide-crisis safeguards are also concerning. The tool under-triaged more than half of cases that physicians determined required emergency care, highlighting the need for caution when relying on AI guidance.
Researchers developed a molecular monitoring approach to identify patients with muscle-invasive bladder cancer who can safely preserve their bladder without compromising cancer outcomes. The study found that ultra-sensitive testing of tumor-derived DNA in blood and urine may help predict metastatic risk and identify patients with an ex...
A Mount Sinai-led study developed an AI tool that analyzes ECGs to identify patients at risk for harmful heart changes, potentially reducing the need for expensive and time-consuming cardiac MRI scans. The tool could make lifelong heart monitoring more accessible and efficient for people born with congenital heart disease.
Researchers used advanced chemical detection to estimate a newborn's total PFAS exposure, detecting 42 confirmed or putatively identified PFAS chemicals in umbilical cord blood. The study found that infants are exposed to a wide range of PFAS before birth, including perfluorinated chemicals and fluorotelomers.
Researchers from The Mount Sinai Hospital have developed an AI-assisted tool to diagnose severe congenital heart defects from fetal scans with high sensitivity and specificity. Additionally, a machine learning model can predict placenta accreta spectrum based on preconception data, identifying novel predictors like anemia.
A new Mount Sinai study strengthens landmark evidence supporting lung-sparing surgery for pleural mesothelioma, a rare and aggressive cancer caused by asbestos exposure. The research found zero in-hospital and 30-day mortality rates, and a 90-day mortality rate of 4.2 percent in carefully selected patients.
Researchers found that patients with major depressive disorder share immune abnormalities with inflammatory skin diseases, including atopic dermatitis. The study suggests targeting the Th2 pathway and interleukin-4 receptor alpha as potential therapeutic strategies for psychiatric illness.
The study found that a novel subset of white blood cells becomes infected in the lung and produces type 1 interferon, which triggers cardiac damage. A modified mRNA treatment was shown to mitigate cardiac damage while preserving the immune system's protective response. The research offers great promise for developing new therapies to p...
A Mount Sinai study found that antibody-producing immune cells called IgG1 plasma cells help patients respond to PD-1 immune checkpoint inhibitors, which have transformed cancer care. The researchers identified IgG1 plasma cells as a critical factor in determining clinical outcomes.
Researchers provide radiation oncologists with practical guidance to identify and protect female sexual organs during pelvic cancer treatment. The study establishes a shared, standardized approach to identifying the bulboclitoris, enabling clinicians to measure radiation dose to these tissues.
Researchers at Mount Sinai detail how decades of cancer vaccine research have converged into more precise and effective immunotherapies. Decades-long clinical trials show personalized neoantigen vaccines are safe and capable of generating robust immune responses across various cancers.
Researchers have characterized the association between cellular senescence and human brain structure in both development and late life. The study found that senescence-related gene expression is linked to brain volume and cortical organization, with distinct roles depending on cell type and stage of life.
Scientists have developed a novel immunotherapy approach that targets tumor macrophages, converting them from immune suppressors to killers. The therapy, using engineered CAR T cells, has shown promising results in preclinical models of metastatic ovarian and lung cancer.
A recent study published in Nature identified over 100 new genetic regions linked to schizophrenia that had not been previously discovered. These findings show that while specific genetic variants may differ across populations, the core biological mechanisms underlying schizophrenia are shared worldwide.
Exposure to PFAS is associated with insulin resistance and altered insulin secretion, identifying pregnancy as a key vulnerable period. Gestational diabetes increases the risk of pregnancy complications and long-term health risks for both mother and child.
Researchers identified bradycardia as a symptom of xylazine-opioid overdose, particularly in the Northeast, where xylazine is more prevalent. This finding may aid emergency medicine physicians in detecting xylazine exposure and providing harm reduction counseling.
Researchers analyzed nearly 1.5 million immune cells from bone marrow samples of 335 newly diagnosed multiple myeloma patients, revealing previously hidden patterns in immune system behavior. The study provides unprecedented insight into immune dysfunction in myeloma and could lead to improved tools for predicting patient relapse risk.
The Mount Sinai Health System has launched an AI-powered clinical trial-matching platform, PRISM, to help connect patients with life-saving trials. The platform uses machine learning to match patients with trials based on their electronic health records and diagnosis.
The Mount Sinai Hospital has received an $8.5 million NIH grant renewal to continue groundbreaking research on long-term outcomes for children with congenital heart disease. The project will unite clinical leaders and registry data from all 25 congenital heart surgical centers across four states to study how differences in health care ...
Researchers at Mount Sinai have developed an AI-powered ECG analysis tool that shows promise in detecting Chronic Obstructive Pulmonary Disease (COPD) early. The model achieved high accuracy rates across diverse populations, including a subgroup with irregular heartbeat and smoking exposure.
Researchers developed an AI tool, NutriSightT, to predict underfeeding in critically ill ICU patients. The model analyzed routine data to identify patients at risk on days 3-7 of ventilation, enabling clinicians to adjust care and provide targeted nutrition.
The Mount Sinai Health System has received a Level 9 designation from CHIME Digital Health Most Wired survey, recognizing its commitment to excellence in digital health. The organization is leveraging AI and digital tools to improve patient care and streamline operational processes.
The Icahn School of Medicine at Mount Sinai is advancing women's health through cutting-edge research and compassionate care, with a focus on addressing knowledge gaps and promoting seamless treatment journeys. The institution joins the Milken Institute's Women's Health Network to bring its expertise in clinical excellence, research in...
Researchers have created an mRNA system that activates therapeutic genes in specific cell populations, potentially leading to safer and more precise cancer treatments. The system uses microRNAs to recognize cancer cells and shuts off the treatment if it's not needed, reducing toxicity and expanding mRNA therapy's reach.
A novel AI tool called V2P has been developed to identify not just genetic mutations but also the diseases they may cause. The method accelerates genetic diagnostics and aids in discovering new treatments for complex and rare diseases by predicting disease outcomes.
Researchers from Mount Sinai present new discoveries in breast cancer biology, treatment, and real-world patient outcomes. The institution's contributions span artificial intelligence, triple-negative breast cancer, geriatric oncology, and novel therapeutic approaches.
A Mount Sinai study found that the timing of a genetic mutation in children with leukemia can significantly impact its aggressiveness. The researchers discovered that leukemia caused by mutations occurring before birth is often more aggressive and harder to treat than those occurring later in life.
A Mount Sinai study reveals PTSD may accelerate brain aging in World Trade Center responders, with longer exposure duration further amplifying the effect. The study uses deep learning-based brain age models to estimate brain age and provides new evidence for the long-term impact of trauma on neurological health.
The Mount Sinai Hospital is now using an FDA-approved AI tool that enhances fetal ultrasound screenings for congenital heart defects. The AI tool improved detection rates of suspicious findings to over 97%, while also reducing reading time and increasing confidence scores.
A novel mRNA-based therapy has been shown to slow bacterial growth, strengthen immune cell activity, and reduce lung tissue damage in models of multidrug-resistant pneumonia. The therapy works by giving the body a special protein that directly breaks down harmful bacteria and recruits immune cells to help clear them out.
Rocatinlimab shows durable improvements in skin clearance, itch, and quality of life by targeting OX40 immune receptor in patients with moderate-to-severe atopic dermatitis. The treatment led to significant reductions in eczema severity, itch, pain, and sleep disturbances.
Researchers at Mount Sinai discovered a technique to renew aged blood-forming stem cells by correcting defects in lysosomes. The breakthrough revealed that restoring lysosomal slow degradation can revitalize aged stem cells and enhance their regenerative capacity. This study may help prevent age-related blood disorders and improve stem...
A new electronic application highlights discrepancies between parents and children's views on the child's well-being, providing powerful insight into how children truly cope. This approach has broad implications beyond transplant medicine and may reshape patient-reported outcomes for pediatric chronic illnesses.
A new study found that current cardiac screening tools are not optimal and fail to identify half the people who are at risk of having a heart attack. The researchers assessed the accuracy of widely used tools, including ASCVD and PREVENT calculators, and found that nearly half of patients would not have been recommended for preventive ...
Researchers at the Icahn School of Medicine created a comprehensive map showing how antibodies attach to the SARS-CoV-2 virus and how viral mutations weaken that attachment. The study highlights the limits of current antibodies and suggests new strategies for building longer-lasting antibody therapies and vaccines.
The initiative aims to decipher the basic function of human genomic sequences, enabling personalized diagnosis and therapy. The partnership will analyze genomic regions to identify underlying mechanisms that contribute to disease and uncover potential therapeutic targets.
A nationwide analysis found that roughly 25% of patients with Bell's palsy received CT or MRI scans within 30 days of diagnosis, not aligned with current guidelines. This study highlights the need for initiatives to align clinical practice with evidence-based guidelines, promoting early treatment and minimizing unnecessary imaging.
A Mount Sinai study found that diverse T cells and low immunosuppressive myeloid cells are key to long-term remission after CAR T cell therapy. Patients with these immune features remained cancer-free for more than five years, while others relapsed sooner.
Renowned gastroenterologist Jean-Frédéric Colombel, MD, will deliver the 31st Anatomy Lesson on November 20, exploring Mount Sinai's pioneering work in IBD prevention and treatment. His presentation aims to highlight the growing problem of immune diseases, including Crohn's disease.
Researchers have identified a distinct population of neuroprotective microglia that may point to a new therapeutic approach for Alzheimer's disease. Microglia with reduced expression of PU.1 and co-expression of CD28 limit neuroinflammation and slow amyloid plaque build-up.
The Mount Sinai Health System will implement Microsoft Dragon Copilot, an AI-powered voice assistant designed to streamline clinical documentation and automate administrative tasks. The rollout aims to reduce burnout, improve patient experiences, and enhance clinical efficiency across the system.
A naturally occurring gene called Cyclin A2, normally silenced in humans, can make new functioning heart cells and aid in the heart's repair. The breakthrough discovery could lead to new techniques for repairing damaged hearts as an alternative to transplants or implanted cardiac devices.
A small phase I study has shown that directly injecting an immune-activating compound into prostate tumors before surgery appears safe and may help the immune system recognize and attack cancer cells. The therapy, called poly-ICLC, was well tolerated and appeared to jump-start immune activity.
The Mount Sinai Tisch Cancer Center has introduced a real-time data integration tool to automate the transfer of clinical data from its electronic health record system into clinical trial platforms. This technology streamlines data flow, reducing manual transcription time by up to 70% and improving data quality and workforce efficiency.
Dr. Bruce D. Gelb, MD, is selected as recipient of the 2026 APS John Howland Award for his groundbreaking work on congenital heart disease (CHD) and related developmental disorders. His research has significantly expanded the scientific understanding of CHD and opened new avenues for diagnostic approaches.